AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
REVA Medical, Inc. (ASX:RVA)
REVA Medical, Inc. (ASX:RVA) is a medical device company which is based in San Diego, California. The companyâs product Fantom Encore is a sirolimus-eluting bioresorbable scaffold (BRS) which is used to treat patients who are suffering from coronary artery disease. In December, the company launched the first implant of its Fantom Encore BRS in Italy. The companyâs other product MOTIV is used to treat patients who are suffering from below-the-knee peripheral artery disease.
Recently, the company expanded its geographical footprint to 7 news European Countries with the addition of 4 new distribution partnerships. It is expected that these partnerships will help the company in expanding access to its Fantom Encore drug-eluting bioresorbable scaffold and these partnerships will also add to the Companyâs commercial momentum.
As at 30 September 2018, the company had Total current assets of $8,725k and total current liabilities $2,937k. In the September quarter, the company the company incurred a net loss of $9,036k with the basic loss per share of $0.22. As at 30 September 2018, the company had net cash used for operating activities of $12,150k and Net cash from investing activities of $700k. At the end of September quarter, the company had Cash and cash equivalents of $7,094k.
In the past six months, the share price of the company decreased by 34.48 percent as on 25 January 2019. RVAâs shares last traded at $0.190 (-20.833% intraday) with a market capitalization of circa $99.62 million as on 25 January 2019.
K2FLY Limited (ASX:K2F)
Technology Company, K2FLY Limited (ASX:K2F) provides innovative, tailored software solutions and consulting services to its clients. In the December quarter (Q2 FY 2019), the company raised invoices to the value of around $863k which was around 31 percent higher than the equivalent quarter last year. During the quarter, no SAP-led Infoscope sales occurred, however, the company is in negotiations with various major prospective clients. The company and its Infoscope team are very much focused on achieving multiple Infoscope sales during the remainder of FY 2019 and beyond. The company is currently engaged in several joint sales campaigns with SAP to a number of significant Tier 1 resources companies. Further, the company is focusing its efforts on signing SAP clients who require a land management solution which resides on the S4 HANA cloud environment.
During Q2 FY 2019, the company made good progress with the Mobile Inspection and Works Management project within Arc Infrastructure, based upon the Fieldreach solution which K2F re-sells on behalf of Capita (UK). As at 31 December 2018, the company had Net cash used in operating activities of $780k and net cash from financing activities of $1,705k. At the end of December quarter, the company had cash and cash equivalent of $995k.
In the last six months, the share price of the company decreased by 43.39 percent as on 25 January 2019. K2Fâs shares traded at $0.135 (-20.588% intraday) with a market capitalization of circa $11.34 million as on 25 January 2019.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
